Komori
M&A and Subsidiary Changes7462CAPITA Inc.Retail

Notice of Completion of the Acquisition of バイオ・サイト・キャピタル株式会社 as a Wholly Owned Subsidiary (Progress Disclosure)

The remaining shares of バイオ・サイト・キャピタル株式会社 were acquired, making the company a wholly owned subsidiary with a 100% voting rights ownership ratio. This has established a structure under which 100% of the company's earnings will be reflected in consolidated results.

Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
1.23
¥100 million
Wording
Conditional
How definitive the wording is.

This transaction

Making the company a wholly owned subsidiary through a share transfer
Disclosing companyCAPITA Inc.
バイオ・サイト・キャピタル株式会社Voting rights ownership percentageNumber of shares acquired 5,921 common shares, representing 5,921 voting rights

The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.

TimelineThe spacing between the points is proportional to the actual number of days.
Target company

1. Laboratory business 2. Fund business 3. Other related businesses incidental to the above

Location Ibaraki, Osaka PrefectureShare capital ¥83.150 million (as of 29 May 2026)Date of incorporation 18 December 2002
Net Sales¥156.825 million (fiscal year ended December 2025)
Net income for the current fiscal year¥10.363 million (fiscal year ended December 2025)
Net assets¥341.861 million (fiscal year ended December 2025)
Consideration and expenses
Acquisition price¥123 million
Impact on Business Performance

The impact on consolidated results for the fiscal year ending March 2027 is immaterial. If any impact or other matters requiring disclosure become known or arise in the future, they will be disclosed promptly.

This transaction
ItemDetails
Transaction nameMaking the company a wholly owned subsidiary through a share transfer
Name of the Subject Companyバイオ・サイト・キャピタル株式会社
Business Description of the Subject Company1. Laboratory business 2. Fund business 3. Other related businesses incidental to the above
Location of the Subject CompanyIbaraki, Osaka Prefecture
Capital Stock of the Subject Company¥83.150 million (as of 29 May 2026)
Date of Establishment of the Subject Company18 December 2002
Net Sales of the Subject Company¥156.825 million (fiscal year ended December 2025)
Net Income of the Subject Company¥10.363 million (fiscal year ended December 2025)
Net Assets of the Subject Company¥341.861 million (fiscal year ended December 2025)
Acquisition price¥123 million
Number of shares acquired5,921 common shares, representing 5,921 voting rights
Voting rights ownership percentageBefore 63.76% → after 100%
Impact on Business PerformanceThe impact on consolidated results for the fiscal year ending March 2027 is immaterial. If any impact or other matters requiring disclosure become known or arise in the future, they will be disclosed promptly.
Date of board resolution22 April 2026
Contract Date29 May 2026
Execution Date / Effective Date29 May 2026 (completed and effective on the same date)
Items this document does not state (16)
Counterparty nameOperating Profit of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To enable agile management decision-making as a unified group amid rapidly changing market conditions. Making the company a wholly owned subsidiary will eliminate the need to consider minority shareholders and reduce coordination costs, establishing a structure that enables the rapid and flexible deployment of management resources and restructuring of the business portfolio.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of the Acquisition of バイオ・サイト・キャピタル株式会社 as a Wholly Owned Subsidiary (Progress Disclosure) | CAPITA Inc. (7462) timely disclosure | Komori